GRF Green Rise Foods Inc

Theratechnologies (TSX:TH) announced today that a distribution and licensing
agreement was signed with sanofi-aventis ("Sanofi"), for the commercialization
rights to EGRIFTA(TM) (tesamorelin for injection) in Latin America, Africa and
the Middle East for the treatment of excess abdominal fat in HIV-infected
patients with lipodystrophy. 


Terms of the Agreement 

Under the terms of the Agreement, Theratechnologies will be responsible to
supply EGRIFTA(TM) to Sanofi. Sanofi will buy EGRIFTA(TM) from Theratechnologies
at an undisclosed selling price. Theratechnologies has kept all future
development rights to EGRIFTA(TM) and will be responsible for conducting
research and development for any additional programs. Sanofi will be responsible
to conduct all regulatory activities in the aforementioned territories in
connection with EGRIFTA(TM) for the treatment of excess abdominal fat in
HIV-infected patients with lipodystrophy, including seeking the approval of
EGRIFTA(TM) in the different countries. Theratechnologies granted Sanofi an
option to commercialize EGRIFTA(TM) in the aforementioned countries for other
uses. 


"Having worked in the sanofi-aventis group for the last 11 years, I am confident
that this collaboration will be a strong and fruitful one for both of us.
Building long-lasting mutually beneficial relationships will be a key to success
for Theratechnologies. This is another critical step towards bringing value to
our shareholders and further demonstrates our ability to execute our business
plan," commented Mr. John-Michel T. Huss, President and CEO of
Theratechnologies. "Sanofi's strong foothold and knowledge in these countries
are invaluable assets to lead the submission process to the various regulatory
agencies. Moreover, Sanofi's extensive commercialization experience, which I
know of first-hand, will be an important aspect of providing market access to
EGRIFTA(TM) as rapidly as possible," concluded Mr. Huss.


"The structure of this agreement clearly emphasizes that we believe strongly in
the potential of EGRIFTA(TM) in these territories," noted Mr. Luc Tanguay,
Senior Executive Vice President and CFO of Theratechnologies. "This transaction
is structured for Theratechnologies to receive a fair percentage of the selling
price which will have a direct effect on our recurring revenues, and on the
bottom-line, as we do not need to directly increase our expenses in order to
achieve these revenues," concluded Mr. Tanguay.


Conference Call and Webcast 

The Company will hold a conference call and webcast today at 8:30 a.m. to
discuss this strategic agreement. To participate, please dial: 1-416-981-9000 or
1-800-785-6380 (toll free). Please dial-in five minutes prior to the
teleconference in order to ensure your participation. The webcast will be
available on the Company's website at http://www.theratech.com and at
http://www.gowebcasting.com/2144.


A replay of the conference call will be available from 10:30 a.m. today,
December 6, 2010, until December 20, 2010, at 11:59 p.m. at the following
number: 1-416-626-4100, pass code 21495399# or 1-800-558-5253, pass code
21495399#. The webcast will be posted for 15 days at the link indicated above.


About EGRIFTA(TM)

EGRIFTA(TM)(tesamorelin for injection) is a synthetic analogue of the human
growth hormone releasing factor ("GRF") shown to reduce visceral fat in
HIV-infected patients with excess abdominal fat associated with lipodystrophy.
GRF is a hypothalamic peptide that acts on the pituitary cells in the brain to
stimulate the synthesis and release of endogenous growth hormone. EGRIFTA(TM) is
approved for sale in the United States only.


About HIV-Associated Lipodystrophy 

Several factors, including a patient's antiretroviral drug regimen and the HIV
virus itself, are thought to contribute to HIV-associated lipodystrophy, which
is characterized by body composition changes. The changes in body composition
may include excess abdominal fat accumulation, which is known as abdominal
lipohypertrophy.


About Theratechnologies 

Theratechnologies (TSX:TH) is a Canadian biopharmaceutical company that
discovers and develops innovative therapeutic products, with an emphasis on
peptides. The Company targets unmet medical needs in specialty markets where it
can retain all or part of the commercial rights to its products. Its most
advanced product, tesamorelin, an analogue of the human growth hormone releasing
factor, was recently approved by the U.S. Food and Drug Administration as the
first and only treatment for excess abdominal fat in HIV-infected patients with
lipodystrophy. Tesamorelin is being exclusively commercialized in the U.S. by
EMD Serono under the brand name EGRIFTA(TM).


For more information, please visit www.theratech.com 

About sanofi-aventis 

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and
distributes therapeutic solutions to improve the lives of everyone.
Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).


For more information on Sanofi-aventis, visit http://www.sanofi-aventis.com 

Forward-Looking Information 

This press release contains certain statements that are considered
"forward-looking information" within the meaning of applicable securities
legislation. This forward-looking information includes, but is not limited to:
information regarding the growth of Theratechnologies. 


Forward-looking information is based upon a number of assumptions and is subject
to a number of risks and uncertainties, many of which are beyond the Company's
control that could cause actual results to differ materially from those that are
disclosed in or implied by such forward-looking information. The assumptions
made include, among others, that regulatory agencies in countries outside of the
United States will also approve EGRIFTA(TM), and that Sanofi will be successful
in commercializing EGRIFTA(TM) in the territories outlined in this press
release. These risks and uncertainties include, but are not limited to: the risk
that EGRIFTA(TM) is not approved by regulatory agencies outside of the United
States, or the risk that the commercialization efforts for EGRIFTA(TM) do not
result in the expected growth of the Company.


The Company refers potential investors to the "Risks and Uncertainties" section
of its Annual Information Form (the "AIF") dated February 23, 2010. The AIF is
available at www.sedar.com under the Company's public filings. The reader is
cautioned to consider these and other risks and uncertainties carefully and not
to put undue reliance on forward-looking statements. Forward-looking information
reflects current expectations regarding future events and speaks only as of the
date of this press release and represents the Company's expectations as of that
date.

Green Rise Foods (TSXV:GRF)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024

Green Rise Foods (TSXV:GRF)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024